{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 42 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Visit 2', 'SGRQ, KBILD and UCSD SOBQ', 'Adverse events and concomitant therapy assessment since last visit', 'Download/review PROactive Tool and activity monitor results', 'Physical examination including vital signs', 'Resting SpO2', 'Blood samples for laboratory tests', 'Urinary pregnancy test', 'Pulmonary function test including FVC', 'DLco', 'Assessment of in/exclusion criteria', 'Randomisation via IRT', '6 minute walk test', 'Schedule patient for pulmonary rehabilitation if randomized to that treatment', 'group', 'Schedule Visit 3', 'Send HRCT for calculation of QLF if not previously available.', 'Visits 3, 4, 5 and 6:', 'Adverse events and concomitant therapy assessment since last visit', 'Collect and download/review PROActive Tool from eDiary and activity', 'monitor data at Visit 5', 'Review pulmonary rehabilitation attendance with patient and record', 'information from pulmonary rehabilitation reports into eCRF for patients in', 'the PR treatment group at Visits 3, 4 and 5', 'Physical examination including vital signs', 'Blood samples for laboratory tests', 'Urinary pregnancy test', 'SGRQ, KBILD and UCSD SOBQ at Visit 5', 'Pulmonary function test including FVC at Visit 5', 'DLCO at Visit 5', 'SP02 at Visit 5', 'Six minute walk test at Visit 5', 'Instruct patient on activity monitoring and eDiary (or eDiary application for', 'own device)and remind patient they need to pick up or will receive device in', 'the mail to allow 7 days of use prior to next visit at Visits 4 and 6', 'Schedule next visit.', '6.2.3', 'Follow up period and trial completion', 'Visit 7/End of Treatment (EOT) or when the patient is discontinued', 'Adverse events and concomitant therapy assessment since last visit', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 43 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Review pulmonary rehabilitation attendance with patient and record information from', 'pulmonary rehabilitation reports into eCRF for patients in the PR treatment group (for', 'patients discontinued during first 12 weeks)', 'Physical examination including vital signs', 'SGRQ, KBILD and UCSD SOBQ', 'Collect and download/review PROActive Tool from eDiary and activity monitor data', 'Resting SpO2', 'Resting 12-lead electrocardiogram', 'Blood samples for laboratory tests', 'Urinary pregnancy test (done locally)', 'Pulmonary function test including FVC', 'DLco', 'Six minute walk test', 'End Of Treatment page to be completed', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 44 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '7.', 'STATISTICAL METHODS AND DETERMINATION OF', 'SAMPLE SIZE', '7.1', 'STATISTICAL DESIGN - MODEL', 'This is a multi-centre, prospective, randomised, open label clinical trial to investigate the', 'effect of pulmonary rehabilitation in patients with IPF currently treated with nintedanib at a', 'dose of 150 mg bid for up to 30 months.', 'The primary endpoint is the change from baseline in 6MWD at 12 weeks. 6MWD will be', 'analysed on the original scale using the Analysis of Covariance (ANCOVA) model including', 'intervention as a fixed categorical covariate and baseline 6MWD as a continuous covariate.', 'More detail is provided in Section 7.3.1.', 'The secondary and further endpoints are listed in Section 5.1.1. The 12-week endpoints will', 'be analysed using similar ANCOVA methodology as the primary endpoint. The 24-week', 'endpoints will be analyzed using a mixed model with repeated measures. More detail is', 'provided in Section 7.3.2.', '7.2', 'NULL AND ALTERNATIVE HYPOTHESES', 'The objective of this study is to demonstrate the difference of Nintedanib and pulmonary', 'rehabilitation combination intervention compared to Nintedanib-only in the treatment of', 'patients with IPF. This will be tested using the set of hypotheses indicated below. The null', 'hypothesis is', 'HO: No difference in mean for change in 6MWD at 12 weeks between Nintedanib and', 'pulmonary rehabilitation combination intervention and Nintedanib-only intervention.', 'The alternative hypothesis is', 'Ha: The mean for change in 6MWD at 12 weeks is different for patients taking', 'Nintedanib and pulmonary rehabilitation combination intervention than in Nintedanib-', 'only intervention.', 'HO will be tested at the 5% level (two-sided test).', '7.3', 'PLANNED ANALYSES', 'All individual data will be listed. Standard statistical parameters (number of non-missing', 'values, mean, geometric mean, standard deviation (SD), median, quartiles, minimum and', 'maximum) or frequency tables will be calculated where appropriate. In general, these', 'parameters or frequencies will be calculated separately for each intervention, but jointly for', 'all study centres.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}